Statement: the least progression free survival(pfs) observed in cohort 1 of the primary clinical trial was lesser than 3 weeks
Primary_evidence: Outcome Measurement:    Progression Free Survival   PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1.   Assessment period was from the day of randomisation until the first observation of lesion progression or death   Time frame: Baseline, every 6 weeks of study treatment period, and end of study, Results 1:    Arm/Group Title: NK105   Arm/Group Description: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle   Overall Number of Participants Analyzed: 211   Median (95% Confidence Interval)   Unit of Measure: months  8.4        (7.0 to 9.9) Results 2:    Arm/Group Title: Paclitaxel   Arm/Group Description: received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle   Overall Number of Participants Analyzed: 211   Median (95% Confidence Interval)   Unit of Measure: months  8.5        (6.9 to 11.5)